TMDX
TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
Article Summary
HOLD- TransMedics Group Inc. (Nasdaq: TMDX) announced that it will release financial results for the second quarter 2026 after market close on Tuesday, August 4, 2026, with Transmedics Group's management team hosting a corresponding conference call beginning at 4:30 p.m.
- The medical technology company is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, founded to address the unmet need for more and better organs for transplantation.
- TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs, developing technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase organ utilization.
- Investors interested in listening to the conference call may do so by dialing 800-715-9871 for domestic callers or (646- 307-1963 for international callers and providing access code 6054544.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 30.2% | 25% | 85.0 ptsExcellent (30.2%) - Strong growth |
| EPS Growth Next 5Y ? | -2.4% | 25% | 0.0 ptsNegative (-2.4%) - Declining expectations |
| Target Price Upside ? | 53.5% | 20% | 100.0 ptsMassive Upside (53.5%) - Target: $114.00 vs Current: $74.29 |
| Gross Margin % ? | 58.8% | 15% | 80.0 ptsVery Healthy (58.8%) - High-quality margins |
| Drawdown from 52-Wk High ? | -52.4% | 15% | 100.0 ptsDeep Discount (-52.4%) - Best entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About TMDX
- TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
- The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
- Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
- The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.
- The company was founded in 1998 and is headquartered in Andover, Massachusetts.